Comprehensive 340B Services to Assist Healthcare Organizations CHAN

For many healthcare organizations serving atrisk populations, the 340B Drug Pricing Program offers a significant source of cost savings. In recent years, the U.S. Health Resources and Services Administration (HRSA) has increased its scrutiny of healthcare organizations to ensure compliance with the myriad of regulations and to reduce potential fraud. Healthcare organizations that aren’t conducting sufficient monitoring and oversight run the risk of disqualification from the 340B Program. CHAN Healthcare has worked with hundreds of healthcare organizations to help them retain this benefit, improve their bottom lines, and enhance ongoing monitoring capabilities.